You are here:

Home
NICE Guidance
Conditions and diseases
Cancer
Breast cancer

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance
Reference number: TA265
Published: 24 October 2012

Guidance
Tools and resources
Information for the public
History

Bone metastases from solid tumours - denosumab: Consultee and commentator comments on the ACD

Bone metastases from solid tumours - denosumab: Amgen (manufacturer)
Bone metastases from solid tumours - denosumab: British Uro-Oncology group
Bone metastases from solid tumours - denosumab: Royal College of Nursing
Bone metastases from solid tumours - denosumab: Royal College of Physicians
Bone metastases from solid tumours - denosumab: Healthcare Improvement Scotland
Bone metastases from solid tumours - denosumab: Prostate Action

This page was last updated: 16 August 2012